Over the past few months, a cluster of "research peptides" that have lived almost entirely in animal studies and online forums — BPC-157, GHK-Cu, TB-500, MOTS-c — suddenly appeared on ClinicalTrials.gov as registered, placebo-controlled human trials.[1][2][3][4] On the surface, that looks like the human evidence these compounds have always lacked is finally arriving.
Look closer and a different picture emerges. Every one of these trials traces to a single sponsor, runs at a single hospital, and was posted within a few weeks of the others. The same sponsor's broader portfolio includes a self-run "Phase 3" of a drug another company already sells, and a trial that reuses a competitor's internal compound code. That pattern is not what a credible, independent evidence base looks like. It is the kind of self-registration that should raise questions — not hopes.
- A registration is not a result. Listing a trial on ClinicalTrials.gov requires no peer review and no proof of efficacy or safety.[8]
- All of these peptide trials share one sponsor (Hudson Biotech) and one site (Peking University Shenzhen Hospital, China), with near-identical early-2026 start dates.
- The same sponsor registered a Phase 3 of tirzepatide — a drug Eli Lilly already markets — and a retatrutide trial reusing Lilly's internal code "LY3437943."[5][6]
- None of this changes our assessment: these peptides still lack credible human RCT evidence.
Quick facts
- Sponsor
- Hudson Biotech (Hudson Tianjin Biotechnology)
- Trial site
- One hospital, Shenzhen, China
- Peptides registered
- BPC-157, GHK-Cu, TB-500, MOTS-c (and more)
- Study starts
- Clustered around Feb–Apr 2026
- Peer-reviewed results
- None — these are registrations only
- Evidence status
- Unchanged: no credible human RCT data yet
What was actually registered
Four of the peptides our readers ask about most now have ClinicalTrials.gov records. On their own, each looks like a reasonable, modern study design:
- BPC-157 — a Phase 2, double-blind, placebo-controlled trial in acute grade II hamstring strain, enrolling 120 participants, first posted February 27, 2026.[1]
- GHK-Cu — a Phase 2, vehicle-controlled, split-wound study of a topical copper-peptide gel for skin-wound re-epithelialization, enrolling 60 participants, first posted February 27, 2026.[2]
- TB-500 (thymosin β4 17-23 fragment) — a Phase 1/2 study of cardiovascular biomarkers in adults with stable atherosclerotic cardiovascular disease, enrolling 80 participants, first posted March 23, 2026.[3]
- MOTS-c — a Phase 2a study of insulin sensitivity in adults with prediabetes and overweight/obesity, enrolling 120 participants, first posted April 1, 2026.[4]
These are real records. The trial numbers resolve, the protocols read coherently, and the placebo/vehicle controls are exactly what rigorous evidence requires. If these studies were independent, ran to completion, and published clean results in peer-reviewed journals, that would genuinely move the needle.
But before treating any of that as evidence, it is worth asking who is running them — and why they all look the same.
Why a registration is not evidence
ClinicalTrials.gov is a registry, not a referee. Sponsors submit their own records; the registry's job is transparency — to publicly log that a study exists and what it intends to measure — not to vouch for the science.[8] A listing does not mean a trial has been peer-reviewed, that it will finish, that its results will be published, or that the compound is safe or effective. Plenty of registered trials are never completed, and registered results are not the same as results that have survived independent scrutiny.
This is the core point we want readers to hold onto: a ClinicalTrials.gov entry is a registration, not a result, not peer review, and not evidence of safety or efficacy. It is the beginning of a process that, done well, takes years and multiple independent groups.
The pattern that warrants skepticism
What turns these listings from "encouraging" into "treat with caution" is the pattern across the sponsor's full portfolio. The same sponsor — listed as Hudson Biotech (Hudson Tianjin Biotechnology) — has registered roughly eight trials, all at the same single site, Peking University Shenzhen Hospital in Shenzhen, China, with starts clustered in early 2026. Several specific records stand out:
- A sponsor-run "Phase 3" trial of tirzepatide (NCT07481747) — a drug Eli Lilly already markets as Mounjaro and Zepbound — listing more than 2,500 participants, with a title that mirrors Lilly's own SURMOUNT-1 program.[5] A small sponsor independently launching a Phase 3 of another company's marketed, patented drug at a single hospital is not how pivotal trials normally work.
- A retatrutide trial (NCT07467447) that reuses Eli Lilly's internal compound code, "LY3437943," and a near-verbatim Lilly protocol title.[6] Internal development codes are company-specific; seeing one reused by an unrelated sponsor is a notable red flag.
- Another record under the same sponsor and site is a Melanotan II for vitiligo trial, again with an early-2026 start.[7]
Taken individually, none of these facts proves wrongdoing, and we are careful not to assert intent we cannot verify. But taken together — one small sponsor, one site, a near-simultaneous wave of placebo-controlled trials spanning unrelated indications, a self-run Phase 3 of a competitor's marketed drug, and the reuse of a competitor's internal compound code — this is the kind of self-registration pattern that, historically, correlates with low-credibility or even fraudulent listings rather than with serious, independent drug development. Reporting also links the Hudson name to research-peptide vendor branding, which would give such a sponsor a marketing incentive to point to "registered clinical trials." We flag that connection cautiously, because it is not something we can fully confirm from primary records.
What we are and are not saying. We are not accusing anyone of fraud. We are describing verifiable facts: one sponsor, one site, a clustered wave of self-registered trials, a sponsor-run Phase 3 of a marketed competitor drug, and the reuse of a competitor's internal compound code. Each of those is checkable on ClinicalTrials.gov. Our point is narrow — these registrations do not constitute the credible, independent human evidence these peptides still lack.
What this changes about the evidence — nothing
It is tempting to read "BPC-157 is now in a placebo-controlled Phase 2 trial" as a sign that the compound has graduated into legitimacy. It has not. The evidence base for BPC-157, GHK-Cu, TB-500, and MOTS-c remains where our profiles describe it: heavily preclinical, concentrated in a small number of labs, and effectively without credible controlled human data.
A single sponsor registering a trial does not change any of that. If anything, the structure of this particular wave — concentrated, simultaneous, and entangled with marketed competitor drugs at one site — is a reason to wait for independent replication and peer-reviewed publication before updating any conclusions. Results that are never published, or that come only from a sponsor with obvious red flags, do not meet the bar for evidence we apply to every other claim on this site.
For how to separate a credible study from a credible-looking listing, see our guide on how to verify a certificate of analysis — the same skeptical habits apply to reading a trial record.
What this means for you
If you use or are considering one of these peptides, here is how to weigh this news.
Do not treat a registration as a green light. A trial appearing on ClinicalTrials.gov tells you a study has been proposed and logged, not that the compound works or is safe. None of these trials has reported peer-reviewed results, and some may never finish.
Check the source the way you would check a seller. Notice who the sponsor is, how many sites are involved, whether the design is independent, and whether the same group is making implausible claims elsewhere (such as running a Phase 3 of a drug it does not own). A single sponsor at a single site, with a portfolio full of red flags, is not the basis for confidence.
Wait for independent, published results. Credible evidence is replicated across groups and survives peer review. When trials like these report — if they report — we will read the actual data critically and tell you whether it holds up, rather than treating the existence of a trial as the story.
Talk to a provider. If you are interested in any of these peptides for a specific condition, a knowledgeable healthcare provider can help you weigh the genuine evidence — which, for now, remains thin.
For the full evidence picture on each compound, see our profiles for BPC-157, GHK-Cu, TB-500, and MOTS-c. And for the first independently framed BPC-157 trial coverage, see our earlier piece on the first BPC-157 RCT.
References
- [1]ClinicalTrials.gov (sponsor: Hudson Biotech). “A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of Pentadecapeptide BPC 157 for Accelerated Repair of Acute Grade II Hamstring Strain Confirmed by MRI.” 2026. Link
BPC-157, acute grade II hamstring strain. Phase 2, n=120. Single site (Peking University Shenzhen Hospital, China). Study first posted 2026-02-27. A registration record, not a result.
- [2]ClinicalTrials.gov (sponsor: Hudson Biotech). “A Phase 2, Randomized, Double-Blind, Vehicle-Controlled, Split-Wound Study of Topical GHK-Cu Gel to Accelerate Re-Epithelialization of Standardized Acute Skin Wounds in Healthy Adults.” 2026. Link
GHK-Cu, topical wound healing. Phase 2, n=60. Same single site. Study first posted 2026-02-27.
- [3]ClinicalTrials.gov (sponsor: Hudson Biotech). “A Phase 1/2 Study of TB-500 (Thymosin Beta 4 17-23 Fragment) in Adults With Stable Atherosclerotic Cardiovascular Disease.” 2026. Link
TB-500 / thymosin β4 (17-23), cardiovascular biomarkers in stable ASCVD. Phase 1/2, n=80. Same single site. Study first posted 2026-03-23.
- [4]ClinicalTrials.gov (sponsor: Hudson Biotech). “A Phase 2a Study to Evaluate the Efficacy, Safety, and Pharmacodynamics of MOTS-c in Adults With Prediabetes and Overweight/Obesity.” 2026. Link
MOTS-c, prediabetes / insulin sensitivity. Phase 2a, n=120. Same single site. Study first posted 2026-04-01.
- [5]ClinicalTrials.gov (sponsor: Hudson Biotech). “Efficacy and Safety of Tirzepatide Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight-Related Comorbidities.” 2026. Link
Sponsor-run Phase 3 of tirzepatide — a drug already marketed by Eli Lilly as Mounjaro/Zepbound. n=2,539 listed, same single site. The title mirrors Lilly's SURMOUNT-1 program. Study first posted 2026-03-19.
- [6]ClinicalTrials.gov (sponsor: Hudson Biotech). “A Phase 2 Study of Once-Weekly LY3437943 Compared With Placebo in Participants Who Have Obesity or Are Overweight With Weight-Related Comorbidities.” 2026. Link
Retatrutide trial that reuses Eli Lilly's internal compound code 'LY3437943' and a near-verbatim Lilly protocol title. n=300, same single site. Study first posted 2026-03-12.
- [7]ClinicalTrials.gov (sponsor: Hudson Biotech). “A Phase 2 Study of Melanotan II as an Adjunct to Narrowband UV-B Phototherapy in Adults With Stable Nonsegmental Vitiligo.” 2026. Link
Melanotan II for vitiligo. Phase 2, n=60. Same single site. Study first posted 2026-02-27.
- [8]U.S. National Library of Medicine. “ClinicalTrials.gov — Background and About the Registry.” 2026. Link
ClinicalTrials.gov is a registry. Sponsors self-submit records; listing does not constitute review, validation, or endorsement of a study's scientific merit or results.
Stay informed
Get evidence-based peptide updates. No spam, no vendor pitches — just the research and regulatory changes that matter.
Related content
BPC-157
Full research profile covering mechanism, animal evidence, and the gap in credible human data.
PeptideTB-500
Recovery peptide often discussed alongside BPC-157. Research profile and evidence assessment.
PeptideGHK-Cu
Copper-peptide complex studied for skin and wound applications. Evidence and safety review.
PeptideMOTS-c
Mitochondrial-derived peptide explored for metabolic effects. What the evidence does and does not show.
GuideHow to Verify a Certificate of Analysis
The skeptical habits that help you tell a credible source from a credible-looking one.
NewsThe First BPC-157 RCT
Our earlier coverage of the first registered BPC-157 trial — and why one trial is a start, not a finish line.
Disclaimer
This article is for educational purposes only. BPC-157, GHK-Cu, TB-500, and MOTS-c are not FDA-approved drugs; they are not available by prescription and are not compoundable. The clinical-trial records described are self-submitted registrations, not peer-reviewed results, and a ClinicalTrials.gov listing is not evidence of safety or efficacy. This is not medical advice or an endorsement of any peptide product. Always consult a licensed healthcare provider before using any peptide.